MedTrace Logo

Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye

NCT00799552 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2010-09-24

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of RX-10045 to placebo for the treatment of the signs and symptoms of dry eye.

Conditions

  • Dry Eye Syndrome

Interventions

DRUG

RX-10045

RX-10045 eye drop

DRUG

Placebo

Placebo eye drop

Sponsors & Collaborators

  • Resolvyx Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Gail Torkildsen, MD · Ophthalmic Research Associates, Andover, MA

  • John Lonsdale, MD · Central Maine Eye Care, Lewiston, ME

  • Joel Geffin, MD · The Eye Care Group, Waterbury, CT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-05-31
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00799552 on ClinicalTrials.gov